East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Linagliptin Tablets, 5 mg. Aurobindo Pharma’s Linagliptin Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Tradjenta Tablets manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer).

Linagliptin Tablets are indicated :

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.